KAI-407

KAI-407 is an orally active inhibitor of Plasmodium PI4K kinase, which can broadly inhibit multiple stages of the parasite lifecycle. KAI-407 exhibits EC50s of for the blood stage of malignant Plasmodium of 81 nM; for the liver schizonts of P. yoelii of 88 nM; and IC50s for the liver schizonts and dormant bodies of P. cynomolgi of 0.64 μM and 0.69 μM respectively. KAI-407 can prevent Plasmodium berghei infection 100%. KAI-407 can be used for the study of vivax malaria[1][2].

1513879-18-9

12352005

Parasite; PI4K

Anti-infection; PI3K/Akt/mTOR

Infection

O=C(C1=CN2C(C=N1)=NC=C2C3=CC=C(C(F)(F)F)C=C3)N(C4=CC=C(C#N)C=C4)C

C22H14F3N5O

421.37

[1]Zou B, et al. Lead optimization of imidazopyrazines: a new class of antimalarial with activity on Plasmodium liver stages. ACS Med Chem Lett. 2014 Jul 6;5 (8) :947-50. |[2]Zeeman AM, et al. KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro. Antimicrob Agents Chemother. 2014;58 (3) :1586-95.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-18746/

Reference compound1

No Development Reported